REG - IQ-AI Limited - IQAI’s Sponsored Phase I Clinical Trial is Open

IQ-AIAnnouncement

09/03/2022 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220309:nRSI2319Ea&default-theme=true

RNS Number : 2319E  IQ-AI Limited  09 March 2022

FOR IMMEDIATE RELEASE

IQ-AI LIMITED

("IQ-AI" or the "Company")

IQAI's Sponsored Phase I Clinical Trial is Open

 

Milwaukee - 9 March 2022:  IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI) is
pleased to announce that the sponsored Phase I clinical trial for oral gallium
maltolate (GaM) is open for enrolment. The trial is being led by Dr. Jennifer
Connelly, MD, Associate Professor of Neurology, and Dr. Christopher Chitambar,
MD, Emeritus Professor of Medicine and Biophysics, Division of Hematology and
Oncology, both at the Medical College of Wisconsin (MCW). Patient recruitment
in the trial is underway and potential volunteers that meet the inclusion
criteria have already been identified.

 

This Phase I dose escalation study is designed to determine the optimal dose
of GaM that can be administered safely. It is the first-in-human clinical
trial for an oral form of GaM to be used in patients with high-grade brain
tumours.

 

"I applaud the efforts of everyone involved in qualifying a new encapsulation
supplier and preparing the necessary documentation to the FDA, and that the
start of this much anticipated trial is now finally underway," said Trevor
Brown, CEO of IQAI.

 

The Directors of the Company accept responsibility for the contents of this
announcement

 

-ENDS-

 

For further information, please contact:

 

 IQ-AI Limited

 Trevor Brown/Brett Skelly/Vinod Kaushal

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law
(as defined in the European Union (Withdrawal) Act 2018).

 

About IQ-AI Limited

IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of
Wisconsin-based Imaging Biometrics, LLC (IB), develops and provides
visualisation and analytical solutions that enable clinicians to better
diagnose and treat disease with greater confidence. Through close
collaboration with top researchers and clinicians, sophisticated advancements
are translated into platform-independent and automated software plug-ins which
can extend the base functionality of workstations, imaging systems, PACS, or
medical viewers. By design, IB's advanced visualisation software seamlessly
integrates into routine workflows. For more information about Imaging
Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDJLMATMTMMBJT